摘要
目的探讨清漾汤颗粒辅助治疗原发性肾病综合征(PNS)患儿的临床效果。方法选取PNS患儿78例,按就诊单双号随机分为中西医治疗组(观察组)和西医治疗组(对照组),每组39例。2组均给予基础西医药物治疗,观察组同时服用清漾汤颗粒治疗,疗程均为12周。比较2组患儿治疗前后肾功能指标[包括血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量、β2-微球蛋白(β2-MG)等]及血清可溶性尿激酶型纤溶酶原激活物受体(suPAR)、可溶性髓样细胞触发受体-1(sTREM-1)、胆固醇(TC)、白蛋白(ALB)、免疫球蛋白(包括IgA、IgM、IgG等)水平。结果治疗前,2组Scr、BUN、24 h尿蛋白定量、β2-MG、suPAR、sTREM-1、TC、ALB、IgA、IgM、IgG水平比较差异均无统计学意义(P>0.05)。治疗后,观察组24 h尿蛋白定量、β2-MG、suPAR、sTREM-1、TC水平均显著低于对照组(P<0.05),ALB水平显著高于对照组(P<0.05),Scr、BUN、IgA、IgM、IgG水平与对照组比较差异均无统计学意义(P>0.05)。结论清漾汤颗粒辅助治疗PNS患儿能更有效地调节血清suPAR、sTREM-1、TC、ALB水平,改善患儿肾功能。
Objective To investigate the clinical efficacy of Qingyangtang granules in adjuvant treatment of children with primary nephrotic syndrome(PNS).Methods According to the odd or even number,78 PNS children were randomly treated with basic Western medicine alone(control group,n=39)or in combination with Qingyangtang granules(observation group,n=39)for 12 weeks.Serum levels of creatinine(Scr),urea nitrogen(BUN),24 h urinary protein quantification,β2-microglobulin(β2-MG),soluble urokinase-type plasminogen activator receptor(suPAR),soluble triggering receptor expressed on myeloid cells-1(sTREM-1),cholesterol(TC),albumin(ALB),immunoglobulin G(IgG),immunoglobulin M(IgM)and immunoglobulin A(IgA)were compared between the two groups.Results There were no significant differences in the levels of Scr,BUN,24 h urinary protein quantification,β2-MG,suPAR,sTREM-1,TC,ALB,IgA,IgM and IgG between the two groups before treatment(P>0.05).After treatment,24 h urine protein quantitation,β2-MG,suPAR,sTREM-1 and TC levels in the observation group were lower than those in the control group,and the level of ALB in the observation group was higher than that in the control group(P<0.05).No significant differences in Scr,BUN,IgA,IgM and IgG levels were found between the two groups after treatment(P>0.05).Conclusion Adjuvant treatment with Qingyangtang granules can effectively regulate serum suPAR,sTREM-1,TC and ALB levels and improve renal function in children with PNS.
作者
亢贞
孙林成
KANG Zhen;SUN Lin-cheng(Department of Laboratory Medicine,Nanyang First People’s Hospital,Nanyang 473000,China;Department of Nephrology,Nanyang First People’s Hospital,Nanyang 473000,China)
出处
《实用临床医学（江西）》
CAS
2023年第1期44-47,共4页
Practical Clinical Medicine
关键词
中成药
清漾汤颗粒
原发性肾病综合征
可溶性尿激酶型纤溶酶原激活物受体
可溶性髓样细胞触发受体-1
肾功能
儿童
Chinese patent medicine
Qingyangtang granules
primary nephrotic syndrome
soluble urokinase-type plasminogen activator receptor
soluble triggering receptor expressed on myeloid cells-1
renal function
children
